Stammdaten
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Unternehmen & Branche
| Name | ESSA Pharma Inc. |
|---|---|
| Ticker | EPIX |
| CIK | 0001633932 |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Marktkapitalisierung | 9,5 Mio. USD |
| Beta | 1,53 |
| Dividendenrendite | 1,69 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-06-30 | 10-Q | -4,003,274 | -0.09 | 110,502,100 | 108,902,145 | |
| 2025-03-31 | 10-Q | -6,374,787 | -0.14 | 115,415,420 | 113,546,504 | |
| 2024-12-31 | 10-Q | -8,531,931 | 122,634,340 | 118,767,004 | ||
| 2024-09-30 | 10-K | -28,542,821 | -0.64 | 128,112,003 | 124,605,770 | |
| 2024-06-30 | 10-Q | -7,233,747 | -0.16 | 132,666,307 | 128,861,543 | |
| 2024-03-31 | 10-Q | -8,989,535 | -0.20 | 137,896,175 | 133,468,859 | |
| 2023-12-31 | 10-Q | -5,964,322 | -0.14 | 144,489,279 | 140,682,939 | |
| 2023-09-30 | 10-K | -26,582,343 | -0.60 | 149,122,131 | 145,627,060 | |
| 2023-06-30 | 10-Q | -7,298,873 | -0.17 | 153,650,198 | 150,242,548 | |
| 2023-03-31 | 10-Q | -7,060,239 | -0.16 | 158,504,040 | 156,337,659 | |
| 2022-12-31 | 10-Q | -6,741,882 | -0.15 | 165,003,340 | 162,019,922 | |
| 2022-09-30 | 10-K | -35,103,251 | -0.80 | 169,505,295 | 167,118,478 | |
| 2022-06-30 | 10-Q | -8,826,743 | -0.20 | 175,660,846 | 171,515,806 | |
| 2022-03-31 | 10-Q | -10,854,604 | -0.25 | 182,609,005 | 178,714,934 | |
| 2021-12-31 | 10-Q | -9,097,919 | -0.21 | 191,486,149 | 187,539,408 | |
| 2021-09-30 | 10-K | -36,805,461 | -0.96 | 198,165,818 | 194,005,552 | |
| 2021-06-30 | 10-Q | -8,752,011 | -0.21 | 203,524,045 | 199,697,583 | |
| 2021-03-31 | 10-Q | -12,965,247 | -0.36 | 210,001,054 | 205,408,071 | |
| 2020-12-31 | 10-Q | -6,528,704 | 76,174,988 | 74,101,365 | ||
| 2020-09-30 | 10-K | -23,445,370 | 80,574,565 | 79,243,865 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-08-05 | BVF PARTNERS L P/IL | 10% Owner | Open Market Sale | -11 | 1.88 | -20.66 | -21,2% | |
| 2025-08-05 | BVF PARTNERS L P/IL | 10% Owner | Open Market Sale | -66 | 1.88 | -123.94 | -126,9% | |
| 2025-08-05 | BVF PARTNERS L P/IL | 10% Owner | Open Market Sale | -79 | 1.88 | -148.35 | -151,9% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.